ARTICLE | Clinical News
SYL040012: Phase IIa data
June 10, 2013 7:00 AM UTC
A double-blind, dose-ranging, European Phase IIa trial in 80 patients with ocular hypertension or open-angle glaucoma showed that once-daily 300 µg SLY040012 eye drops for 14 days met the primary endp...